Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple guide help clinicians better address youth substance use?

NCT ID NCT07725289

Knowledge-focused Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 24, 2026 · Last updated Sep 09, 2026 · Updated 3 times

Summary

This study develops and pilot tests a written 'practice companion' designed to help clinicians and other trusted adults provide developmentally appropriate substance use care to youth ages 14 to 24. The companion offers practical guidance on cannabis, opioids, and other substances, with a focus on overdose prevention and harm reduction. Researchers will interview youth, families, and clinicians to assess whether the care is acceptable, useful, and feasible in hospital and community settings.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a written practice companion guiding clinicians in youth substance use care
What this could lead to
If successful, this practice companion could offer a practical tool to improve substance use care for adolescents and young adults, potentially reducing overdose risk.
What could go wrong
This is a small pilot study with only 60 participants, so results may not generalize. The intervention is behavioral and depends on clinician uptake, which may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

14 to 24 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Ages 14 to 24 years. * Uses drugs or alcohol (past year). * Receiving care at a participating study site. Exclusion Criteria: * Cognitive limitations or intellectual disabilities that prevent provision of informed consent. * Any medical or psychiatric condition causing acute distress or requiring emergency evaluation. * Current membership on a study Community Advisory Board.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adolescent substance use are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cannabis dependence Drug Overdose Harm Reduction opiate dependence poisoning substance abuse substance-related disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adolescent substance use Cannabis use Co-occurring mental health conditions Drug overdose Opioid-use disorder Overdose prevention Substance use Substance-related disorders

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    5 sites in 2 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Adolescent and Young Adult Medicine, Mass General Brigham for Children

    Boston, Massachusetts, 02114, United States

  • BC Children's Hospital

    Vancouver, British Columbia, V6H 3N1, Canada

  • CHU Sainte-Justine

    Montreal, Quebec, H3T 1C5, Canada

  • Centre de Recherche du CHUM (CRCHUM)

    Montreal, Quebec, H2X 0A9, Canada

  • Foundry (Foundry Central Office)

    Vancouver, British Columbia, Canada

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.